The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Epirubicin     (7S,9R)-7-[(2S,4S,5R,6S)-4- amino-5-hydroxy...

Synonyms: Farmorubicin, IMI-28, IMI 28, NSC-256942, NSC256942, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of IMI 28


Psychiatry related information on IMI 28


High impact information on IMI 28


Chemical compound and disease context of IMI 28


Biological context of IMI 28


Anatomical context of IMI 28


Associations of IMI 28 with other chemical compounds


Gene context of IMI 28


Analytical, diagnostic and therapeutic context of IMI 28


  1. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Jensen, B.V., Nielsen, S.L., Skovsgaard, T. Lancet (1996) [Pubmed]
  2. Epirubicin-induced primary Sjögren's syndrome. Oxholm, A., Frederiksen, P.L., Oxholm, P. Lancet (1986) [Pubmed]
  3. Production of the antitumor drug epirubicin (4'-epidoxorubicin) and its precursor by a genetically engineered strain of Streptomyces peucetius. Madduri, K., Kennedy, J., Rivola, G., Inventi-Solari, A., Filippini, S., Zanuso, G., Colombo, A.L., Gewain, K.M., Occi, J.L., MacNeil, D.J., Hutchinson, C.R. Nat. Biotechnol. (1998) [Pubmed]
  4. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen. Zuckerman, K.S., Case, D.C., Gams, R.A., Prasthofer, E.F. Blood (1993) [Pubmed]
  5. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Hunz, M., Jetter, A., Warm, M., Pantke, E., Tuscher, M., Hempel, G., Jaehde, U., Untch, M., Kurbacher, C., Fuhr, U. Clin. Pharmacol. Ther. (2007) [Pubmed]
  6. Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Fraser, S.C., Dobbs, H.J., Ebbs, S.R., Fallowfield, L.J., Bates, T., Baum, M. Br. J. Cancer (1993) [Pubmed]
  7. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Woo, I.S., Moon, d.o. .H., Shim, B.Y., Lee, M.A., Byun, J.H., Kim, K.W., Kang, J.H., Choi, M.G., Chung, I.S., Hong, Y.S., Park, S.Y., Lee, K.S. Jpn. J. Clin. Oncol. (2005) [Pubmed]
  8. Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C. Mikami, M., Ezawa, S., Sakaiya, N., Komuro, Y., Tei, C., Fukuchi, T., Mukai, M. Lancet (2000) [Pubmed]
  9. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Wieder, T., Essmann, F., Prokop, A., Schmelz, K., Schulze-Osthoff, K., Beyaert, R., Dörken, B., Daniel, P.T. Blood (2001) [Pubmed]
  10. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. Knoop, A.S., Knudsen, H., Balslev, E., Rasmussen, B.B., Overgaard, J., Nielsen, K.V., Schonau, A., Gunnarsdóttir, K., Olsen, K.E., Mouridsen, H., Ejlertsen, B. J. Clin. Oncol. (2005) [Pubmed]
  11. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Mamot, C., Drummond, D.C., Noble, C.O., Kallab, V., Guo, Z., Hong, K., Kirpotin, D.B., Park, J.W. Cancer Res. (2005) [Pubmed]
  12. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. Praga, C., Bergh, J., Bliss, J., Bonneterre, J., Cesana, B., Coombes, R.C., Fargeot, P., Folin, A., Fumoleau, P., Giuliani, R., Kerbrat, P., Hery, M., Nilsson, J., Onida, F., Piccart, M., Shepherd, L., Therasse, P., Wils, J., Rogers, D. J. Clin. Oncol. (2005) [Pubmed]
  13. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. Conte, P.F., Bruzzone, M., Carnino, F., Gadducci, A., Algeri, R., Bellini, A., Boccardo, F., Brunetti, I., Catsafados, E., Chiara, S., Foglia, G., Gallo, L., Iskra, L., Mammoliti, S., Parodi, G., Ragni, N., Rosso, R., Rugiati, S., Rubagotti, A. J. Clin. Oncol. (1996) [Pubmed]
  14. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. Reni, M., Passoni, P., Panucci, M.G., Nicoletti, R., Galli, L., Balzano, G., Zerbi, A., Di Carlo, V., Villa, E. J. Clin. Oncol. (2001) [Pubmed]
  15. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. Venturini, M., Bruzzi, P., Del Mastro, L., Garrone, O., Bertelli, G., Guelfi, M., Pastorino, S., Rosso, R., Sertoli, M.R. J. Clin. Oncol. (1996) [Pubmed]
  16. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. Jain, K.K., Casper, E.S., Geller, N.L., Hakes, T.B., Kaufman, R.J., Currie, V., Schwartz, W., Cassidy, C., Petroni, G.R., Young, C.W. J. Clin. Oncol. (1985) [Pubmed]
  17. Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. Frustaci, S., Buonadonna, A., Galligioni, E., Favaro, D., De Paoli, A., Lo Re, G., Sorio, R., Tumolo, S., Monfardini, S. J. Clin. Oncol. (1997) [Pubmed]
  18. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Rouzier, R., Rajan, R., Wagner, P., Hess, K.R., Gold, D.L., Stec, J., Ayers, M., Ross, J.S., Zhang, P., Buchholz, T.A., Kuerer, H., Green, M., Arun, B., Hortobagyi, G.N., Symmans, W.F., Pusztai, L. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  19. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Tjuljandin, S.A., Doig, R.G., Sobol, M.M., Watson, D.M., Sheridan, W.P., Morstyn, G., Mihaly, G., Green, M.D. Cancer Res. (1990) [Pubmed]
  20. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. Venturini, M., Lunardi, G., Del Mastro, L., Vannozzi, M.O., Tolino, G., Numico, G., Viale, M., Pastrone, I., Angiolini, C., Bertelli, G., Straneo, M., Rosso, R., Esposito, M. J. Clin. Oncol. (2000) [Pubmed]
  21. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. Perez, D.J., Harvey, V.J., Robinson, B.A., Atkinson, C.H., Dady, P.J., Kirk, A.R., Evans, B.D., Chapman, P.J. J. Clin. Oncol. (1991) [Pubmed]
  22. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C., Robey, R., Pommier, Y., Fojo, T., Bates, S.E. Cancer Res. (1999) [Pubmed]
  23. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer. Lalisang, R.I., Wils, J.A., Nortier, H.W., Burghouts, J.T., Hupperets, P.S., Erdkamp, F.L., Schouten, H.C., Blijham, G.H. J. Clin. Oncol. (1997) [Pubmed]
  24. A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. de Vries, E.G., Greidanus, J., Mulder, N.H., Nieweg, M.B., Postmus, P.E., Schipper, D.L., Sleijfer, D.T., Uges, D.R., Willemse, P.H. J. Clin. Oncol. (1987) [Pubmed]
  25. Distribution and toxic effects of intravenously injected epirubicin on the central nervous system of the mouse. Bigotte, L., Olsson, Y. Brain (1989) [Pubmed]
  26. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor. Basser, R.L., To, L.B., Begley, C.G., Maher, D., Juttner, C., Cebon, J., Mansfield, R., Olver, I., Duggan, G., Szer, J., Collins, J., Schwartz, B., Marty, J., Menchaca, D., Sheridan, W.P., Fox, R.M., Green, M.D. J. Clin. Oncol. (1998) [Pubmed]
  27. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. Rischin, D., Corry, J., Smith, J., Stewart, J., Hughes, P., Peters, L. J. Clin. Oncol. (2002) [Pubmed]
  28. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Chambers, S.K., Hait, W.N., Kacinski, B.M., Keyes, S.R., Handschumacher, R.E. Cancer Res. (1989) [Pubmed]
  29. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B., Brown, R. Cancer Res. (2000) [Pubmed]
  30. Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. Salvatorelli, E., Guarnieri, S., Menna, P., Liberi, G., Calafiore, A.M., Mariggiò, M.A., Mordente, A., Gianni, L., Minotti, G. J. Biol. Chem. (2006) [Pubmed]
  31. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Kool, M., van der Linden, M., de Haas, M., Baas, F., Borst, P. Cancer Res. (1999) [Pubmed]
  32. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Burger, H., Foekens, J.A., Look, M.P., Meijer-van Gelder, M.E., Klijn, J.G., Wiemer, E.A., Stoter, G., Nooter, K. Clin. Cancer Res. (2003) [Pubmed]
  33. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Innocenti, F., Iyer, L., Ramírez, J., Green, M.D., Ratain, M.J. Drug Metab. Dispos. (2001) [Pubmed]
  34. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Im, S.A., Kim, S.B., Lee, M.H., Im, Y.H., Lee, K.H., Song, H.S., Lee, M.A., Lee, J., Lee, N.S., Ham, H.S., Kim, T.Y., Park, Y.H., Lee, K.E., Kim, K.W., Seo, J.H., Lee, S.N., Hong, Y.S., Bang, Y.J., Kim, W.K., Park, H.S. Oncol. Rep. (2005) [Pubmed]
  35. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Han, B., Zhang, J.T. Current medicinal chemistry. Anti-cancer agents. (2004) [Pubmed]
  36. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. Crump, M., Tu, D., Shepherd, L., Levine, M., Bramwell, V., Pritchard, K. J. Clin. Oncol. (2003) [Pubmed]
  37. Chemoradiation and adjuvant chemotherapy in cervical cancer. Wong, L.C., Ngan, H.Y., Cheung, A.N., Cheng, D.K., Ng, T.Y., Choy, D.T. J. Clin. Oncol. (1999) [Pubmed]
  38. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Buzdar, A.U., Ibrahim, N.K., Francis, D., Booser, D.J., Thomas, E.S., Theriault, R.L., Pusztai, L., Green, M.C., Arun, B.K., Giordano, S.H., Cristofanilli, M., Frye, D.K., Smith, T.L., Hunt, K.K., Singletary, S.E., Sahin, A.A., Ewer, M.S., Buchholz, T.A., Berry, D., Hortobagyi, G.N. J. Clin. Oncol. (2005) [Pubmed]
  39. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). Ejlertsen, B., Mouridsen, H.T., Langkjer, S.T., Andersen, J., Sjöström, J., Kjaer, M. J. Clin. Oncol. (2004) [Pubmed]
WikiGenes - Universities